Back to top

Imax Q2 outperformance paced by system installations, says Roth Capital

Roth Capital keeps a Buy rating and $48 price target on Imax (IMAX) after the company’s “strong” outperformance in Q2 reported this morning. Upside...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

ImageneBio, Inc. (IMA)

IMAX Corporation (IMAX)